

**IN THE UNITED STATES PATENT
AND TRADEMARK OFFICE**

Serial No. : 10/541,228
Applicants : Keiji HASUMI et al.
Filed : June 29, 2005
For : AFFINITY TRAP REACTOR AND
SINGLE-STEP PROCESS FOR
PURIFYING ANGIOSTATIN-LIKE
FRAGMENT FROM HUMAN PLASMA...
Art Unit : 1614
Docket No. : 05360/HG
Confirm. No.: 4548
Customer No.: 01933

**REPLY TO NOTIFICATION TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO
ACID SEQUENCE DISCLOSURES**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Attention: Barbara A. Campbell

S I R :


This is in reply to the NOTIFICATION TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR
AMINO ACID SEQUENCE DISCLOSURES mailed February 23, 2006, a
response to which is due on April 23, 2006. A copy of said
NOTIFICATION is being transmitted herewith.

**CERTIFICATE OF FACSIMILE
TRANSMISSION**

PTO NO. 1-571-273-8300
1-571-273-9886

TOTAL PAGES: 5

I hereby certify that this
paper is being facsimile
transmitted to the
Commissioner for Patents
on the date noted below.


Attorney: Richard S. Barth

Dated: March 16, 2006

In the event that this Paper
is late filed, and the
necessary petition for
extension of time is not filed
concurrently herewith, please
consider this as a Petition
for the requisite extension of
time, and to the extent not
tendered by check attached
hereto, authorization to
charge the extension fee,
or any other fee required
in connection with this
Paper, to Account No. 06-1378.

Said NOTIFICATION stated the following:

"This application does not contain, as a separate part of the disclosure on paper copy, a 'Sequence Listing' as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the 'Sequence Listing.'

* * *

A copy of the 'Sequence Listing' in computer readable form has not been submitted as required by 37 CFR 1.821(e)."

A Sequence Listing is not required for the following reasons.

37 CFR 1.821(a) defines a nucleotide and an amino acid in context of requiring a Sequence Listing as follows:

"Nucleotide and/or amino acid sequences as used in §§1.821 through 1.825 are interpreted to mean an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides."

The above-identified application does not contain an unbranched sequence of four or more amino acids or an unbranched sequence of ten or more nucleotides. Accordingly, a Sequence Listing is not required.


The only disclosure of any amino acids or nucleotides in the above-identified application are on page 2, line 6 (Glu¹-Ser⁴⁴¹)

and page 2, lines 8 and 9 (Val⁴⁴²-Asn⁷⁹¹). However, Glu¹-Ser⁴⁴¹ and Val⁴⁴²-Asn⁷⁹¹ each do not recite a sequence of four or more amino acids, but rather two amino acids (one amino acid occurring at the beginning of a sequence and one amino acid occurring at the end of a sequence).

In view of the above, withdrawal of the requirement to submit a Sequence Listing is respectfully requested.

Respectfully submitted,

Frishauf, Holtz, Goodman
& Chick, P.C.
220 Fifth Ave., 16th Floor
New York, NY 10001-7708
Tel. No.: (212) 319-4900
Fax No.: (212) 319-5101


Richard S. Barth
REG. NO. 28,180

E-Mail Address: BARTH@FHGC-LAW.COM
RSB/ddf

Enc.: copy of NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR
PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO
ACID SEQUENCE DISCLOSURES dated February 23, 2006

MAR. 16. 2006 11:59AM

Frishauf & Partners +12123195101


 Rec'd PCT/PJ 16 MAR 2006
 NO. 9402 Page 5 of 2


UNITED STATES PATENT AND TRADEMARK OFFICE

 UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/541,228	FIRST NAMED APPLICANT Keiji Hasumi	ATTY. DOCKET NO. 05360/HG
INTERNATIONAL APPLICATION NO. PCT/JP03/00338		LA. FILING DATE 01/17/2003
PRIORITY DATE		

1933

 FRISHAUF, HOLTZ, GOODMAN & CHICK, PC
 220 Fifth Avenue
 16TH Floor
 NEW YORK, NY 10001-7708


CONFIRMATION NO. 4548

371 FORMALITIES LETTER



OC000000018060761

Due 04/23/06

Date Mailed: 02/23/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

MAR. 16. 2006 12:00PM

Frishauf & Partners +12123195101

Rec'd PCT/PTO 16 MAR 2006
NO. 9402 Page 5 of 2

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/541,228	PCT/JP03/00338	05360/HG

FORM PCT/DO/EO/922 (371 Formalities Notice)